Raymond James Initiates Coverage On Xilio Therapeutics with Outperform Rating, Announces Price Target of $16
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.
Raymond James analyst Sean McCutcheon initiates coverage on Xilio Therapeutics (NASDAQ:XLO) with a Outperform rating and announces Price Target of $16.
